Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Pharmacoeconomic Analysis of Therapy with Generic Statin Drugs in Patients with High and Very High Cardiovascular Risk (According to the Study PRIORITY)

https://doi.org/10.20996/1819-6446-2020-10-16

Full Text:

Abstract

Aim. To perform a pharmacoeconomical assessment of the use of generic statin drugs in patients with high and very high cardiovascular risk (CVR) in real clinical practice based on the data of the study PRIORITY.

Material and methods. The PRIORITY study included 298 patients with high (29; 9.7%) and very high (269, 90.3%) CVR. All patients were recommended to take the reproduced drugs of atorvastatin and rosuvastatin in an individually prescribed dose. After 1 month (B1), if the target level of lowdensity lipoprotein cholesterol (LDL-C) was not reached, the statin dose was titrated. After 3 months of follow-up (B3), the hypolipidemic effect of statin therapy was evaluated. 295 people completed the study, 285 patients had the results of the lipid profile. To perform a pharmacoeconomic analysis and evaluate the “cost/effectiveness” ratio, we used the prices of generic statins in one of the online pharmacies. The effectiveness of statins was determined by the LDL-C reduction, as well as by the percentage of achieving the target LDL-C level.

Results. At the first stage of the pharmacoeconomic analysis, the criterion for the effectiveness of 3-month lipid-lowering therapy was a decrease in LDL-C level by 1 mmol/l. The median and interquartile range of the ratio “cost/effectiveness” indicator for atorvastatin was 658.2 (431.5; 1257.1) RUB/mmol/l, and for rosuvastatin – 621.0 (390.7; 940.6) RUB/mmol/l (p=0.45). The results of a comparative assessment of the “cost/effectiveness” ratio (with the abovementioned effectiveness indicator) in subgroups of patients with high and very high CVR, with the achievement and nonachievement of the target level of LDL-C, adherent and non-adherent to statins, revealed the economic advantage of statins in groups of adherent patients (p=0.35), high-risk patients (p<0.0001) and individuals who reached the target level of LDL-C (p=0.002) when compared with the corresponding comparison groups. Despite the revealed high effectiveness of rosuvastatin at doses of 20-40 mg/day (assessed by the cost/effectiveness of achieving the target values of LDL-C for specific doses of statins), calculation of the “cost/effectiveness” ratio for each reproduced statin, in general, showed a higher economic effectiveness of atorvastatin.

Conclusion. Pharmacoeconomic analysis of therapy with generic statin drugs, performed according to the data of the non-randomized uncontrolled study, allows to justify the economic efficiency and advantages of these drugs in various subgroups of patients who need statin therapy.

About the Authors

S. Yu. Martsevich
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Sergey Yu. Martsevich – MD, PhD, Professor, Head of Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990



Yu. V. Lukina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Yulia V. Lukina – MD, PhD, Leading Researcher, Laboratory of Pharmacoepidemiological Studies, Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990



N. P. Kutishenko
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Natalia P. Kutishenko – MD, PhD, Head of Laboratory of Pharmacoepidemiological Studies, Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990



References

1. World Health Organization. The Rational Use of Drugs: Report of the Conference of Experts Nairobi, 1985. World Health Organization; 1985 [cited by Sep 01, 2020]. Available from: https://apps.who.int/iris/handle/10665/37174.

2. Mach F., Baigent C., Catapano A.L., et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. DOI:10.1093/eurheartj/ehz455.

3. Piepoli M.F., Hoes A.W., Agewall S., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;252:207-74. DOI:10.1016/j.atherosclerosis.2016.05.037.

4. Ginzburg M.L., Martsevich S.Y., Kutishenko N.P., et al. The capabilities of a register as a quality control of the pharmacotherapy in outpatients at high risk of cardiovascular complications (the "LIS-1" register). Rational Pharmacotherapy in Cardiology. 2014;10(3):288-92 (In Russ.) DOI:10.20996/1819-6446-2014-10-3-288-292.

5. Martsevich S.Yu., Gaysenok O.V., Tripkosh S.G., et al. Medical supervision in specialized center and the quality of lipid-lowering therapy in patients with cardiovascular diseases (according to the PROFILE register). Rational Pharmacotherapy in Cardiology. 2013;9(2):133-7 (In Russ.) DOI:10.20996/1819-6446-2013-9-2-133-137.

6. Ershova A.I., Meshkov A.N., Yakushin S.S., et al. Diagnosis and treatment of patients with severe hypercholesterolemia in real outpatient practice (according to the RECVASA registry). Rational Pharmacotherapy in Cardiology. 2014;10(6):612-6. (In Russ.) DOI:10.20996/1819-6446-2014-10-6-612-616.

7. Reiner Ž., De Backer G., Fras Z., et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey. Atherosclerosis. 2016;246:243-50. DOI:10.1016/j.atherosclerosis.2016.01.018.

8. Gomez Sandoval Y.H., Braganza M.V., Daskalopoulou S.S. Statin discontinuation in high-risk patients: a systematic review of the evidence. J Clin Lipidol. 2016;10(4):987-95. DOI:10.1016/j.jacl.2016.04.010.

9. Lukina Yu.V., Kutishenko N.P., Martsevich S.Yu. Treatment adherence: modern view on a well-known issue. Cardiovascular Therapy and Prevention. 2017;16(1):91-5 (In Russ.) DOI:10.15829/1728-8800-2017-1-91-95.

10. Kutishenko N.P., Martsevich S.Y., Tolpygina S.N., Lukina J.V. Economic reasons for generic choice. Rational Pharmacotherapy in Cardiology. 2008;4(4):36-9 (In Russ.) DOI:10.20996/1819-6446-2008-4-4-36-39

11. Kesselheim A.S., Avorn J., Sarpatwari A. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. JAMA. 2016;316(8):858-71. DOI:10.1001/jama.2016.11237.

12. Martsevich S.Yu., Lukina Yu.V., Kutishenko N.P., et al. Features and main problems of treating patients with high and very high cardiovascular risk with statins in real clinical practice (according to the data of the “PRIORITET” research). Cardiovascular Therapy and Prevention. 2018;17(6):52-60 (In Russ.) DOI:10.15829/1728-8800-2018-6-52-61.

13. Martsevich S.Yu., Lukina Yu.V., Kutishenko N.P., et al. Adherence to Statins Therapy of High and Very High Cardiovascular Risk Patients in Real Clinical Practice: Diagnostics and Possible Ways to Solve the Problem (According to the PRIORITY Observational Study). Rational Pharmacotherapy in Cardiology. 2018;14(6):891-900 (In Russ.) DOI:10.20996/1819-6446-2018-14-6-891-900.

14. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations, V revision (2012) [cited by Sep 01, 2020]. Available from: http://www.scardio.ru/content/Guidelines/rek_lipid_2012.pdf (In Russ.)

15. Martsevich S.Yu., Lukina Yu.V., Kutishenko N.P., et al. Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study). Rational Pharmacotherapy in Cardiology. 2019;15(6):864-72 (In Russ.) DOI:10.20996/1819-6446-2019-15-6-864-872.

16. Morrison A., Glassberg H. Determinants of the cost-effectiveness of statins. J Manag Care Pharm. 2003;9(6):544-51. DOI:10.18553/jmcp.2003.9.6.544.

17. Kazi D.S., Virani S.S. Implications of cost-effectiveness analyses of lipid-lowering therapies: From the policy-maker's desk to the patient's bedside. Prog Cardiovasc Dis. 2019;62(5):406-13. DOI:10.1016/j.pcad.2019.10.006.

18. Hirsch M, O'donnell J, Olsson A. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. Int J Cardiol. 2005;104(3):251-6. DOI:10.1016/j.ijcard.2004.09.015.

19. Grabner M., Winegar D.A., Punekar R.S., et al. Cost Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level. Am J Cardiol. 2017 Feb 1;119(3):404-9. DOI:10.1016/j.amjcard.2016.10.028.

20. Shulman K.A., Glick H.A., Polsky D. Pharmacoeconomics: Economic evaluation of Pharmaceuticals. Chapter 22. In: Strom BL, Kimmel SE, eds. Textbook of Pharmacoepidemiology.. Phyladelphia, USA: Wiley; 2008. P. 678-708.


For citation:


Martsevich S.Yu., Lukina Yu.V., Kutishenko N.P. Pharmacoeconomic Analysis of Therapy with Generic Statin Drugs in Patients with High and Very High Cardiovascular Risk (According to the Study PRIORITY). Rational Pharmacotherapy in Cardiology. 2020;16(5):693-698. (In Russ.) https://doi.org/10.20996/1819-6446-2020-10-16

Views: 49


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)